Immunotherapy Drug Tebentafusp Improves Survival in Advanced Uveal Melanoma

In a large trial, tebentafusp helped patients with uveal melanoma live longer than patients who received other treatments for the disease. Uveal melanoma is an aggressive cancer of the eye, and many patients do not survive for a year once it has spread.